Navigation Links
Neurologix to Present at the Third Annual C.E. Unterberg Towbin,Emerging Growth Conference

FORT LEE, N.J.--(BUSINESS WIRE)--Jul 6, 2007 - Neurologix, Inc. (OTCBB:NRGX), a biotechnology company engaged in the development of innovative gene therapies for the brain and central nervous system, announced today that the company will present at the Third Annual C.E. Unterberg Towbin Emerging Growth Conference on Tuesday July 10, 2007 at 4:30 pm ET at The Mandarin Oriental Hotel in New York.

President and Chief Executive Officer John Mordock will discuss Neurologix's business and product development. The audio portion of the presentation will be webcast live, and a replay will be available shortly after the actual presentation time for 90 days on the Investor Relations page of the company's website at www.neurologix.net.

About Neurologix

Neurologix, Inc. is a development-stage company engaged in the research and development of proprietary treatments for disorders of the brain and central nervous system utilizing gene therapies. The Company's initial development efforts are focused on gene therapy for treating Parkinson's disease, epilepsy and other neurodegenerative and metabolic disorders. Neurologix's core technology, "NLX," is currently in clinical stages of development, having recently completed a Phase I human clinical trial to treat Parkinson's disease and with additional trials in that indication and in epilepsy planned.

Contact

Neurologix, Inc.
Marc Panoff, 201-592-6451
Chief Financial Officer
marcpanoff@neurologix.net


'"/>




Page: 1

Related medicine technology :

1. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
2. The Past, Present and Future of HLA Typing
3. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
6. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
7. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
8. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
9. ViaCell to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
10. Accelrys to Present to Investors at C.E. Unterberg Emerging Growth Opportunities Conference
11. Metabasis to Present at C.E. Unterberg, Towbin Emerging Growth Conference and Attend Pacific Growth Equities Conference

Post Your Comments:
(Date:11/20/2009)... 20 Soligenix, Inc. (OTC... formerly known as DOR BioPharma, Inc., a late-sta...has formed a consortium to develop thermostable te...ting vaccines. Soligenix received a $9.4 million g...fectious Diseases (NIAID), a division of the Natio...
(Date:11/19/2009)...PRNewswire/ -- In response to an ever-increasing n...medicines, Operation Pangea II, involving 24 count...alth Organization,s International Medical Products...ht the dangers of buying medicines online. ,, T...s of arrests and the seizure of thousands of poten...
(Date:11/19/2009)...Nov. 19 Alexza Pharmaceu... its corporate presentation will be webcast live d...nference on Wednesday, December 2, 2009 at 9:00 a.... from The New York Palace Hotel in New York and wi...t and CEO. ,, To access the live presentation...
Breaking Medicine Technology:Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 2Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 3Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 4Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 5Soligenix Forms Consortium to Develop Thermostable Technology to Advance RiVax(TM) and Other Rapidly Acting Vaccines 6International Operation Combats Online Supply of Counterfeit and Illegal Medicines 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 2Alexza Pharmaceuticals to Present at the 21st Annual Piper Jaffray Health Care Conference 3Quark Pharmaceuticals to Participate in IBCs Oligonucleotide Therapeutics 3A From Concept to Implementation Conference 53480 1Quark Pharmaceuticals to Participate in IBCs Oligonucleotide Therapeutics 3A From Concept to Implementation Conference 53480 2Quark Pharmaceuticals to Participate in IBCs Oligonucleotide Therapeutics 3A From Concept to Implementation Conference 53480 3Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX 0401 28Perifosine 29 in the Treatment 53476 1Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX 0401 28Perifosine 29 in the Treatment 53476 2Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX 0401 28Perifosine 29 in the Treatment 53476 3Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX 0401 28Perifosine 29 in the Treatment 53476 4Keryx Biopharmaceuticals Announces Agreement with FDA on a Special Protocol Assessment for Phase 3 Trial of KRX 0401 28Perifosine 29 in the Treatment 53476 5Oncothyreon announces presentation of long term Stimuvax data at World Conference on Lung Cancer 13328 1Oncothyreon announces presentation of long term Stimuvax data at World Conference on Lung Cancer 13328 2Oncothyreon announces presentation of long term Stimuvax data at World Conference on Lung Cancer 13328 3Oncothyreon announces presentation of long term Stimuvax data at World Conference on Lung Cancer 13328 4
(Date:11/21/2009)...1 Milvia Lopez, by her attorney MI...filed suit, in Supreme Court, New York County, bea...at while Ms. Lopez underwent a routine transesopha...ITAL , doctors used an HIV infected scope exposing...veral hours after being discharged from the proced...
(Date:11/21/2009)... based medical credentialing software company Inte... a partnerhsip with Amerinet, Inc., the leading he... help to transform quality care within the healthc...ember 21, 2009 -- ISG Group, LLC, doing business a... with Amerinet Inc., a leading national healthcare...
(Date:11/21/2009)...w Haven Dental Group merges their practice with th... (PRWEB) November 21, 2009...ers Dr. David Gibson, Dr. Dean Cloutier, Dr. John ... their growing practice with that of esteemed coll...decided he wanted to retire from dentistry in orde...
(Date:11/20/2009).... 20 The American Acad...ealth care reform legislation released this week t...urance individual coverage mandate. The actuaries ...l minimize adverse selection stemming from more re... bill. ,, "The individual mandate language shou...
(Date:11/20/2009)... Nov. 20 Rates of infect...ed in late October, but the pandemic flu virus con...age groups, including the elderly, according to a ...: DGX ), the world,s leading provider of diagnos...ts most recent Quest Diagnostics Health Trends(TM)...
Breaking Medicine News(10 mins):Health News:Patient Files Suit Against St. Vincent's Hospital in New York City as a Result of the Alleged Use by the Hospital of an HIV Infected Device During a Routine Procedure 2Health News:IntelliSoft Group and Amerinet Inc. Form Partnership to Transform Healthcare Delivery of Quality Patient Safety and Care 2Health News:New Haven Dental Group Expands Their Vision 2Health News:Actuaries to Senate: Strengthen Individual Mandate 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 2Health News:H1N1 Pandemic May Have Peaked in October in U.S., According to Quest Diagnostics 3
...Roche announced today that a total of,20 U.S. and ...eloda(R),(capecitabine) have been accepted for pre...mposium (SABCS) in San AntonioDecember 12-14, incl...cts to be presented at the meeting compare the imp...
... 9 , The following is being issued by Norma... Recently there has been a frenzy of articles in...elivery system. We are told there are 46 million,p...care,rescue plan passed within ninety days of Pres...
... Voonami, Inc., a leading provider of outsourc...nounced today the opening of their first of severa...r in Orem, UT. Voonami also announced two new ada...ty of 300 watts per square foot. , ...
... Despite the recent economic downturn, natural...e industry are still experiencing a wellness boom,...rowth. Natural Healers, the Internet,s top natural... centers to help prospective students interested i...
... Full Spectrum - a leading FDA software develo...h the latest information on code obfuscation techn...able now. , (PRWEB) Decem... the impact of using a basic software engineering ...
...Therapeutics, Inc.,(Nasdaq and MTA: CTIC) announce...ter studies utilizing Zevalin(R) ([90Y]-ibritumoma... of Hematology (ASH) 50th Annual Meeting in,San Fr...initial treatment in,15 patients with advanced sta...
Other Medicine News:Health News:Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium 2Health News:Twenty New Abstracts on Oral Xeloda(R) (capecitabine) Featured at the 31st San Antonio Breast Cancer Symposium 3Health News:Average Americans Without Health Insurance Are Young and Healthy With Above Average Incomes 2Health News:Voonami, Inc. Announces Three New Adaptive Data Centers 2Health News:Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier 2Health News:Natural Healers Researches Natural Health Careers to Make the Prospective Holistic Health Students' Job Easier 3Health News:Aimed at Medical Device Makers, FDA Software Development Company Full Spectrum Releases Free Technical Report on Software Protection Technology 2Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 2Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 3Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 4Health News:Three Italian Multicenter Studies Report High (>70%) Rates of Complete Remission (CR) Utilizing Zevalin Radio-Immunotherapy (RIT) in Treatment of Newly Diagnosed or Relapsed or Refractory Non-Hodgkin's Lymphoma 5
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
...oratory and a worldwide leader in innovative labor...ensive test menu of highly complex and unique medi...d by the University of Utah, ARUP Laboratories' cl...rsity teaching hospitals and children's hospitals,...
Medicine Products: